Charles Schwab’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-226,160
| Closed | -$418K | – | 3742 |
|
|
2023
Q1 | $418K | Hold |
226,160
| – | – | ﹤0.01% | 3007 |
|
|
2022
Q4 | $251K | Sell |
226,160
-16,599
| -7% | -$23.6K | ﹤0.01% | 3147 |
|
|
2022
Q3 | $569K | Sell |
242,759
-116
| -0% | -$411 | ﹤0.01% | 2965 |
|
|
2022
Q2 | $736K | Sell |
242,875
-34,413
| -12% | -$167K | ﹤0.01% | 2912 |
|
|
2022
Q1 | $1.88M | Buy |
277,288
+133,610
| +93% | +$952K | ﹤0.01% | 2664 |
|
|
2021
Q4 | $1.2M | Buy |
143,678
+93
| +0.1% | +$766 | ﹤0.01% | 2842 |
|
|
2021
Q3 | $1.07M | Sell |
143,585
-114,507
| -44% | -$709K | ﹤0.01% | 2855 |
|
|
2021
Q2 | $1.76M | Buy |
258,092
+58,069
| +29% | +$482K | ﹤0.01% | 2759 |
|
|
2021
Q1 | $2.06M | Sell |
200,023
-54,500
| -21% | -$597K | ﹤0.01% | 2655 |
|
|
2020
Q4 | $1.78M | Sell |
254,523
-54,861
| -18% | -$427K | ﹤0.01% | 2622 |
|
|
2020
Q3 | $2.52M | Buy |
309,384
+25,065
| +9% | +$155K | ﹤0.01% | 2416 |
|
|
2020
Q2 | $1.96M | Buy |
284,319
+51,234
| +22% | +$276K | ﹤0.01% | 2437 |
|
|
2020
Q1 | $1.11M | Buy |
233,085
+36,347
| +18% | +$209K | ﹤0.01% | 2467 |
|
|
2019
Q4 | $1.72M | Buy |
196,738
+96,051
| +95% | +$519K | ﹤0.01% | 2461 |
|
|
2019
Q3 | $336K | Buy |
100,687
+4,735
| +5% | +$19K | ﹤0.01% | 2943 |
|
|
2019
Q2 | $475K | Buy |
95,952
+1,209
| +1% | +$6.42K | ﹤0.01% | 2834 |
|
|
2019
Q1 | $588K | Buy |
94,743
+10,325
| +12% | +$49.9K | ﹤0.01% | 2704 |
|
|
2018
Q4 | $285K | Buy |
84,418
+8,524
| +11% | +$39.8K | ﹤0.01% | 2953 |
|
|
2018
Q3 | $494K | Buy |
75,894
+27,943
| +58% | +$208K | ﹤0.01% | 2846 |
|
|
2018
Q2 | $368K | Buy |
47,951
+8,103
| +20% | +$117K | ﹤0.01% | 2898 |
|
|
2018
Q1 | $891K | Sell |
39,848
-2,681
| -6% | -$59.5K | ﹤0.01% | 2555 |
|
|
2017
Q4 | $543K | Buy |
42,529
+1,092
| +3% | +$16.1K | ﹤0.01% | 2705 |
|
|
2017
Q3 | $646K | Buy |
41,437
+17,218
| +71% | +$243K | ﹤0.01% | 2648 |
|
|
2017
Q2 | $340K | Buy |
24,219
+11,833
| +96% | +$253K | ﹤0.01% | 2822 |
|
|
2017
Q1 | $273K | Buy |
+12,386
| New | +$262K | ﹤0.01% | 2849 |
|
Other funds holding JNCE
Charles Schwab's JNCE Position: Q2 2023 in Review
Charles Schwab sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 226,160 shares — an estimated $418K sold.
Charles Schwab first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $2.52M in Q3 2020. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.
- Charles Schwab reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Charles Schwab sold 226,160 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $418K.
- Charles Schwab first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
- Charles Schwab's Jounce Therapeutics, Inc. Common Stock position peaked at $2.52M in Q3 2020.
- 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Charles Schwab's 13F filing for Q2 2023, filed 10 Aug 2023.